112 related articles for article (PubMed ID: 7542154)
21. Effect of recombinant human granulocyte colony-stimulating factor in patients receiving methotrexate/vinblastine/doxorubicin/cisplatin therapy for the treatment of transitional cell carcinoma of the urinary tract.
Akaza H; Kotake T; Miyanaga N; Koiso K
Semin Oncol; 1994 Feb; 21(1 Suppl 1):70-4. PubMed ID: 7512280
[No Abstract] [Full Text] [Related]
22. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924.
Sternberg CN; de Mulder PH; Schornagel JH; Théodore C; Fossa SD; van Oosterom AT; Witjes F; Spina M; van Groeningen CJ; de Balincourt C; Collette L;
J Clin Oncol; 2001 May; 19(10):2638-46. PubMed ID: 11352955
[TBL] [Abstract][Full Text] [Related]
23. Treatment of advanced urothelial carcinoma with M-VECA (methotrexate, vinblastine, epirubicin and carboplatin).
Lorusso V; Pagliarulo A; Selvaggi FP; Durini E; Riccardi F; Comella P; Fiorillo C; De Lena M
J Chemother; 1996 Apr; 8(2):154-8. PubMed ID: 8708748
[TBL] [Abstract][Full Text] [Related]
24. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder.
Blick C; Hall P; Pwint T; Al-Terkait F; Crew J; Powles T; Macaulay V; Munro N; Douglas D; Kilbey N; Protheroe A; Chester JD
Cancer; 2012 Aug; 118(16):3920-7. PubMed ID: 22614698
[TBL] [Abstract][Full Text] [Related]
25. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium.
Sternberg CN; Yagoda A; Scher HI; Watson RC; Ahmed T; Weiselberg LR; Geller N; Hollander PS; Herr HW; Sogani PC
J Urol; 1985 Mar; 133(3):403-7. PubMed ID: 4038749
[TBL] [Abstract][Full Text] [Related]
26. [Effect of recombinant human granulocyte colony stimulating factor in patients with transitional cell carcinoma of the urothelium receiving methotrexate, etoposide and cisplatinum combination chemotherapy].
Miura T; Murai T; Shimura H; Kondo I
Hinyokika Kiyo; 1993 Mar; 39(3):209-12. PubMed ID: 7685138
[TBL] [Abstract][Full Text] [Related]
27. Methotrexate, vinblastine, epidoxorubicin and cisplatin (M-VEC) in patients with locally advanced transitional bladder cancer.
Frassoldati A; Federico M; Barbieri F; Brausi M; Pollastri C; Berri G; Castagnetti G; Palladini PP; Silingardi V
Med Oncol Tumor Pharmacother; 1991; 8(2):99-103. PubMed ID: 1749307
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
Segal R; Winquist E; Lukka H; Chin JL; Brundage M; Markman BR;
Can J Urol; 2002 Oct; 9(5):1625-33. PubMed ID: 12431323
[TBL] [Abstract][Full Text] [Related]
29. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
Loehrer PJ; Einhorn LH; Elson PJ; Crawford ED; Kuebler P; Tannock I; Raghavan D; Stuart-Harris R; Sarosdy MF; Lowe BA
J Clin Oncol; 1992 Jul; 10(7):1066-73. PubMed ID: 1607913
[TBL] [Abstract][Full Text] [Related]
30. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study.
Petrioli R; Frediani B; Manganelli A; Barbanti G; De Capua B; De Lauretis A; Salvestrini F; Mondillo S; Francini G
Cancer; 1996 Jan; 77(2):344-51. PubMed ID: 8625244
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience.
Stöckle M; Meyenburg W; Wellek S; Voges GE; Rossmann M; Gertenbach U; Thüroff JW; Huber C; Hohenfellner R
J Urol; 1995 Jan; 153(1):47-52. PubMed ID: 7966789
[TBL] [Abstract][Full Text] [Related]
32. Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer.
Masuda N; Fukuoka M; Kudoh S; Kusunoki Y; Matsui K; Nakagawa K; Hirashima T; Tamanoi M; Nitta T; Yana T
J Clin Oncol; 1994 Jan; 12(1):90-6. PubMed ID: 7505810
[TBL] [Abstract][Full Text] [Related]
33. [Dose intensity in M-VAC chemotherapy with rG-CSF for metastatic transitional urothelial cancer].
Obata K; Kobayashi H; Takaba H; Yokoi K; Hikosaka A
Hinyokika Kiyo; 1994 Oct; 40(10):939-44. PubMed ID: 7527613
[TBL] [Abstract][Full Text] [Related]
34. Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma.
Hsu CH; Chen J; Wu CY; Cheng AL; Pu YS
Anticancer Res; 2001; 21(1B):711-5. PubMed ID: 11299831
[TBL] [Abstract][Full Text] [Related]
35. Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma.
McCaffrey JA; Hilton S; Mazumdar M; Sadan S; Heineman M; Hirsch J; Kelly WK; Scher HI; Bajorin DF
J Clin Oncol; 1997 Jun; 15(6):2449-55. PubMed ID: 9196161
[TBL] [Abstract][Full Text] [Related]
36. Escalated therapy for refractory urothelial tumors: methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosylated recombinant human granulocyte-macrophage colony-stimulating factor.
Logothetis CJ; Dexeus FH; Sella A; Amato RJ; Kilbourn RG; Finn L; Gutterman JU
J Natl Cancer Inst; 1990 Apr; 82(8):667-72. PubMed ID: 2181151
[TBL] [Abstract][Full Text] [Related]
37. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse.
Sternberg CN; Yagoda A; Scher HI; Watson RC; Geller N; Herr HW; Morse MJ; Sogani PC; Vaughan ED; Bander N
Cancer; 1989 Dec; 64(12):2448-58. PubMed ID: 2819654
[TBL] [Abstract][Full Text] [Related]
38. A study of dose escalation of teniposide (VM-26) plus cisplatin (CDDP) with recombinant human granulocyte colony-stimulating factor (rhG-CSF) in patients with advanced small cell lung cancer.
Eguchi K; Etou H; Miyachi S; Morinari H; Nakada K; Noda K; Ohkuni Y; Watanabe K; Yamada Y; Ohe Y
Eur J Cancer; 1994; 30A(2):188-94. PubMed ID: 7512356
[TBL] [Abstract][Full Text] [Related]
39. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
Masuda N; Fukuoka M; Kudoh S; Matsui K; Kusunoki Y; Takada M; Nakagawa K; Hirashima T; Tsukada H; Yana T
J Clin Oncol; 1994 Sep; 12(9):1833-41. PubMed ID: 7521905
[TBL] [Abstract][Full Text] [Related]
40. Results of adjuvant chemotherapy for invasive urothelial cancer with lymph-node metastasis.
Kobayashi H; Obata K
Cancer Chemother Pharmacol; 1994; 35 Suppl():S14-7. PubMed ID: 7994781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
